You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAntazoline
Accession NumberDB08799
TypeSmall Molecule
GroupsApproved
DescriptionAntazoline is a 1st generation antihistamine that also anticholinergic properties used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis.
Structure
Thumb
Synonyms
Antazoline
Vasocon-a
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Albalon AAllergan Inc
Cooper A.R.Coopervision Inc.
Ophtrivin A Ophthalmic DpsCiba Vision Canada Inc
Refresh Eye Allergy ReliefAllergan Inc
Steritears ArLaboratoires Sterigen Inc
Vasocon A Eye DropsNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc
Vasocon A Oph SolnIolab Pharmaceuticals
Zincfrin AAlcon Canada Inc
Salts
Name/CASStructureProperties
Antazoline phosphate
ThumbNot applicableDBSALT001374
Antazoline sulfate
ThumbNot applicableDBSALT000910
Categories
UNIIDHA8014SS1
CAS number91-75-8
WeightAverage: 265.3529
Monoisotopic: 265.157897623
Chemical FormulaC17H19N3
InChI KeyInChIKey=REYFJDPCWQRWAA-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)
IUPAC Name
N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline
SMILES
C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Aniline
  • Imidolactam
  • 2-imidazoline
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis.
PharmacodynamicsAntazoline is a histamine H1 receptor antagonist. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
Mechanism of actionAntazoline binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9699
Blood Brain Barrier+0.9578
Caco-2 permeable-0.5076
P-glycoprotein substrateSubstrate0.7167
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.59
Renal organic cation transporterInhibitor0.8403
CYP450 2C9 substrateNon-substrate0.798
CYP450 2D6 substrateSubstrate0.6581
CYP450 3A4 substrateNon-substrate0.6963
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.919
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9644
CYP450 3A4 inhibitorNon-inhibitor0.952
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.788
CarcinogenicityNon-carcinogens0.896
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5401
hERG inhibition (predictor II)Inhibitor0.5709
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Liquidophthalmic
Dropsophthalmic
Solutionophthalmic
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point227-229Miescher, K. and Klarer, W.; US. Patent 2,449,241; September 14,1948: assigned to Ciba Pharmaceutical Products, Inc.
water solubility663 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.114 mg/mLALOGPS
logP3.22ALOGPS
logP2.88ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)9.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area27.63 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity82.89 m3·mol-1ChemAxon
Polarizability30.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Miescher, K. and Klarer, W.; US. Patent 2,449,241; September 14,1948: assigned to Ciba
Pharmaceutical Products, Inc.

General References
  1. Figus M, Fogagnolo P, Lazzeri S, Capizzi F, Romagnoli M, Canovetti A, Iester M, Ferreras A, Rossetti L, Nardi M: Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. Eur J Ophthalmol. 2010 Sep-Oct;20(5):811-8. [PubMed:20383847 ]
External Links
ATC CodesR01AC04R06AX05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (70.7 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Antazoline.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Antazoline.
AmphetamineAmphetamine may decrease the sedative activities of Antazoline.
BenzphetamineBenzphetamine may decrease the sedative activities of Antazoline.
Benzylpenicilloyl PolylysineAntazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Antazoline.
ChlorphentermineChlorphentermine may decrease the sedative activities of Antazoline.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Antazoline.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Antazoline.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Antazoline.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Antazoline.
MephentermineMephentermine may decrease the sedative activities of Antazoline.
MethamphetamineMethamphetamine may decrease the sedative activities of Antazoline.
PhenterminePhentermine may decrease the sedative activities of Antazoline.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Swiader MJ, Luszczki JJ, Wielosz M, Czuczwar SJ: Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. Pharmacol Rep. 2005 Jul-Aug;57(4):531-5. [PubMed:16129921 ]
Comments
comments powered by Disqus
Drug created on October 14, 2010 14:06 / Updated on August 17, 2016 12:24